PLoS ONE (Jan 2022)

Association between severe hepatic steatosis examined by Fibroscan and the risk of high-risk colorectal neoplasia.

  • Kwang Woo Kim,
  • Hyoun Woo Kang,
  • Hosun Yoo,
  • Yukyung Jun,
  • Hyun Jung Lee,
  • Jong Pil Im,
  • Ji Won Kim,
  • Joo Sung Kim,
  • Seong-Joon Koh,
  • Yong Jin Jung

DOI
https://doi.org/10.1371/journal.pone.0279242
Journal volume & issue
Vol. 17, no. 12
p. e0279242

Abstract

Read online

The prevalence of colorectal neoplasm in patients with non-alcoholic fatty liver disease has increased twice as high as that in the general population. FibroScan is a new modality for evaluating hepatic steatosis. This study aimed to investigate the relationship between the risk of high-risk colorectal neoplasia and hepatic steatosis examined using FibroScan. This was a cross sectional study of prospectively enrolled subjects who were scheduled to undergo index colonoscopy as a health screening between March 2018 and February 2019. The severity of steatosis was graded as normal, mild, moderate, or severe using FibroScan. A total of 140 consecutive subjects were enrolled and sequentially examined using FibroScan and colonoscopy. Subjects with hepatic steatosis had more high-risk colorectal neoplasia than those without hepatic steatosis. In addition, tumor size was larger in subjects with hepatic steatosis. In multivariable analysis, severe hepatic steatosis was an independent risk factor for high-risk colorectal neoplasia (adjusted odds ratio: 3.309, confidence interval: 1.043-10.498, p = 0.042). Alcohol consumption was also identified as a risk factor for high-risk colorectal neoplasia. In conclusion, severe hepatic steatosis on FibroScan is associated with the development of high-risk colorectal neoplasia. Thus, physicians should be aware of the association between colorectal neoplasia and hepatic steatosis assessed by FibroScan and its clinical implications.